Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03877926 · ClinicalTrials.gov registry record · Phase 3
VELOCITY: An Anthrax Vaccine Clinical Study
A Phase 3 study of Anthrax, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,862
- Enrollment target
- 20
- Study locations
NCT03877926: Completed Phase 3 study of Anthrax, sponsored by Emergent BioSolutions.
NCT03877926 is a Phase 3 study of Anthrax that has completed, run by Emergent BioSolutions. The registered enrollment target is 3,862 participants, above the 135-participant average among 6 other Anthrax trials with a reported enrollment target (2761% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03877926, a Phase 3 study of Anthrax, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,862 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the lot consistency (using three consecutively manufactured lots), safety, and ability of the AV7909 anthrax vaccine to generate an immune response in healthy adults and compare the response to that induced by the currently licensed vaccine, BioThrax®, (Anthrax Vaccine Adsorbed; AVA) for post-exposure of anthrax disease.
Primary Outcome
GMT of TNA NF50 at Day 64 in AV7909 study groups (Lots 1, 2 and 3) and BioThrax group. The outcome measure in AV7909 study groups was assessed for AV7909 lot-to-lot consistency, which was based on GMT TNA NF50 response at Day 64, wherein the 95% confidence interval (CI) for ratios of geometric mean titer (GMT) of TNA NF50 at Day 64 (seven weeks after second AV7909 vaccination) for each of the three AV7909 lot-to-lot comparisons had to be within equivalence margin of 0.5 and 2.0.
Conditions Studied
Interventions
- BIOLOGICAL AV7909
- BIOLOGICAL BioThrax
Study Locations (20)
Kansas
- Heartland Research Associates, LLC - Augusta
- Hutchinson Clinic - Hutchinson
- Johnson County Clin-Trials, LLC - Lenexa
- Heartland Research Associates, LLC - Wichita
Alabama
- Achieve Clinical Research, LLC - Birmingham
- Optimal Research, LLC - Huntsville
- Coastal Clinical Research, an AMR company - Mobile
Florida
- Research Centers of America - Hollywood
- Optimal Research, LLC - Melbourne
- New Horizon Research Center, Inc - Miami
Arizona
- Central Phoenix Medical Clinic, LLC - Phoenix
- Clinical Research Consortium, an AMR company - Tempe
California
- California Research Foundation - San Diego
- Optimal Research, LLC - San Diego
Illinois
- Christie Clinic, LLC - Champaign
- Optimal Research, LLC - Peoria
Georgia
- Meridian Clinical Research, LLC - Savannah
Idaho
- Advanced Clinical Research - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,862 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2020-08-06 |
| Phase | Phase 3 |
What the finished NCT03877926 record still lists
NCT03877926 is an interventional study that assigns participants to a tested intervention. Its 3,862 participants enrollment target places it among the larger protocols in the corpus, above the 135-participant average among 6 other Anthrax trials with a reported enrollment target (2761% higher).
The record links to 1 condition, with Anthrax appearing as the primary indexed condition, and to 2 interventions - of which AV7909 is the first listed.
NCT03877926 names 20 study sites across 10 states, led by Kansas, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT03877926 about?
NCT03877926 is a clinical study titled "VELOCITY: An Anthrax Vaccine Clinical Study". This study is designed to evaluate the lot consistency (using three consecutively manufactured lots), safety, and ability of the AV7909 anthrax vaccine to generate an immune response in healthy adults and compare the response to that induced by the currently licensed vaccine, BioThrax®, (Anthrax Vac...
What is the current status of trial NCT03877926?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,862 participants. The study started on 2019-03-11. Estimated completion is 2020-08-06.
What conditions does trial NCT03877926 study?
This clinical trial studies the following conditions: Anthrax.
What interventions are being tested in trial NCT03877926?
The interventions under investigation include: AV7909 (BIOLOGICAL), BioThrax (BIOLOGICAL).
Who is sponsoring clinical trial NCT03877926?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03877926 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anthrax
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
RECRUITING
-
Anthrax AV7909 Boost Evaluation Study
ACTIVE NOT RECRUITING · Phase 2
-
PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine
COMPLETED · Phase 1
-
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
COMPLETED · Phase 2
-
Anthrax Vaccine Clinical Trials
COMPLETED · Phase 1
-
Febrile Whole Blood Specimen Collection and Testing
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07087613 · 3,850 participants
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
- NCT05919342 · 3,904 participants · NA
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
- NCT03936335 · 3,930 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
- NCT04573660 · 3,784 participants
Abbott Vascular Medical Device Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI